Kezar (KZR) stock fell 9% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and adopted a stockholders rights plan. Read more here.
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cone Biopharma (CNTB) experienced a significant stock drop of 5.47%, currently trading at $1.21 per share. The trading volume reached 777 shares, with no notabl
Shares of Saratoga Investment Corp. SAR rose sharply in today's pre-market trading after the company reported better-than-expected earnings and sales results fo...
Overview of the Recent Transaction On October 1, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) made a significant new investment in the biotechnology se
Aileron Therapeutics, Inc. (ALRN) experienced a significant stock drop of 5.15%, with shares priced at $3.46 and a trading volume of 31,420 shares. The stock's
The stock of BeyondSpring Inc. (BYSI) displayed significant volatility, with its value surging by 7.27%. The stock is currently priced at $2.36 per share, featu
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.
/PRNewswire/ -- The autoimmune hemolytic anemia therapeutics market has been segmented by product (corticosteroids, monoclonal antibodies, and others) and...